Eli Lilly disclosed positive top‑line results from the Phase 3 Attain‑Maintain trial: its oral GLP‑1 receptor agonist orforglipron met primary and key secondary endpoints for weight maintenance after prior treatment with injectable incretin therapies. The company reported superior weight maintenance versus placebo over 52 weeks. Lilly formally requested FDA approval for orforglipron and received a national priority voucher that will accelerate the agency’s review timeline. The data support broader positioning of the pill as a maintenance therapy and could expand market share in the obesity treatment landscape already dominated by injectables. Competitor filings from Novo Nordisk for a rival oral agent mean rapid regulatory timelines could decide early market positioning. Analysts view the results as a potential commercial catalyst, but note real‑world adherence and label claims will shape uptake.